Compare FC & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FC | RXST |
|---|---|---|
| Founded | 1983 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.7M | 300.5M |
| IPO Year | 1994 | 2021 |
| Metric | FC | RXST |
|---|---|---|
| Price | $24.37 | $5.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 10 |
| Target Price | ★ $26.00 | $9.78 |
| AVG Volume (30 Days) | 68.7K | ★ 988.3K |
| Earning Date | 04-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $267,067,000.00 | $134,479,000.00 |
| Revenue This Year | $3.15 | N/A |
| Revenue Next Year | $4.04 | $10.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.16 | $4.48 |
| 52 Week High | $25.50 | $13.65 |
| Indicator | FC | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 60.18 | 49.35 |
| Support Level | $23.07 | $4.48 |
| Resistance Level | $25.50 | $7.60 |
| Average True Range (ATR) | 1.22 | 0.29 |
| MACD | -0.08 | 0.11 |
| Stochastic Oscillator | 65.83 | 76.26 |
Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.